O ut-of-hospital cardiac arrest (OHCA) refers to the loss of cardiac mechanical activity with hemodynamic collapse in the out-of-hospital setting. If not treated rapidly, OHCA invariably results in death. Survival to hospital discharge after OHCA is low in many communities, ranging between 10.7% (95% confidence interval, 9.9%-11.5%) for adults treated for all rhythms and 31.7% (95% confidence interval, 28.2%-35.1%) for those resuscitated after bystander-witnessed ventricular fibrillation (VF). 1 The most common cause of death among patients hospitalized after OHCA is neurological injury. 2, 3 In spite of these unmet challenges, the in-hospital mortality rate of treated patients has declined 11.8% in recent years, from 69.6% in 2001 to 57.8% in 2009. 4 This improvement in outcomes is thought to be related in part to the advent of therapeutic hypothermia, as well as implementation of intensive care protocols for those successfully resuscitated but still comatose after OHCA. 4 
Rationale for Hypothermia
Reperfusion injury occurs in the brain 5 and heart 6 during and after restoration of blood flow. It includes release of proinflammatory then anti-inflammatory cytokines, which contribute to poor capillary perfusion, tissue ischemia, and microcirculatory dysfunction. Cardiac function decreases then improves during the initial 2 days. Vascular and intestinal permeability increase during the next 3 days. Patients may experience sepsis-like hemodynamic states, 7 neurological injury, multiple organ dysfunction, and death. The extent of reperfusion injury is associated with the duration of ischemia, and the adequacy of resuscitation. In turn, long-term prognosis is correlated with the extent of reperfusion injury.
Induction of hypothermia during ischemia prolongs the tolerance of organs to ischemia. Hypothermia after reperfusion reduces production of deleterious glutamate, oxygenfree radicals and inflammatory molecules, cerebral oxygen demand, intracranial pressure, and the final extent of neurological injury. 8 Thus, induced hypothermia (IH), sometimes called targeted temperature management, which consists of cooling the body to reduce neurological injury and multiorgan dysfunction, is applied to patients with OHCA. The 2010
Guidelines on Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care recommend that 9 :
comatose (ie, lack of meaningful response to verbal commands) adult patients with restoration of spontaneous circulation (ROSC) after out-of-hospital VF cardiac arrest should be cooled to 32°C to 34°C (89.6°F to 93.2°F) for 12 to 24 hours (Class I, LOE B). Induced hypothermia also may be considered for comatose adult patients with ROSC after in-hospital cardiac arrest of any initial rhythm or after out-ofhospital cardiac arrest with an initial rhythm of pulseless electric activity or asystole (Class IIb, LOE B).
These evidence-based recommendations are being reevaluated in light of recent trials of IH in patients with OHCA. Until then, we offer contemporary evidence-based recommendations for use of IH in this population.
Early Cooling
In considering the optimal timing of mild hypothermia, several animal studies suggest that cooling earlier results in more protection than cooling later. In a mouse model, IH with cooling blankets during CPR was better than IH after restoration of spontaneous circulation (ROSC). 10 In a dog model of VF arrest, mild hypothermia with cold normal saline infusion during CPR was associated with greater survival compared with IH after resuscitation. 11 In another dog model, mild hypothermia during arrest significantly improved cerebral function as compared with normothermia, whereas IH 15 minutes after reperfusion did not. 12 These animal studies suggest that intraarrest cooling or cooling within 15 minutes after ROSC is associated with better neurological recovery.
The optimal timing of the initiation of mild hypothermia in humans remains an important question. In humans, IH started 4 to 8 hours after resuscitation, is associated with improved neurological outcome compared with normothermia. 13, 14 A challenge in testing IH earlier than this in humans is finding a simple and safe method that paramedics can apply in the field to patients with cardiac arrest. Invasive and noninvasive hospital-based methods may not be applicable for use in the field. Invasive strategies using cooling catheters rapidly achieve the goal temperature, but are impractical for field application because they are placed into the inferior vena cava. External cooling techniques have the advantage of being less invasive; however, most of them, including cooling blankets or fluid pads depend on an external energy supply or external cooling unit, and are not practical for field use. Ice packs have been used 13 ; wide application of ice packs is limited because of relatively slow induction times to temperatures <34°C compared with other methods.
Infusion of Cold Fluid
The use of intravenous infusion of ice-cold fluids is appealing because it is portable and easy to administer in the field in patients resuscitated from OHCA, and was initially popularized by the group of Bernard et al 15 The use of early cooling using cold intravenous fluid has been recently addressed by our group, in the largest randomized trial of IH in patients with OHCA reported to date. 17 In this study, 1359 adult patients successfully resuscitated from nontraumatic OHCA (583 with VF and 776 without VF) were randomized to prehospital cooling (n=688; 292 with VF and 396 without VF) versus standard care only (n=671; 291 with VF and 380 without VF) irrespective of the presenting rhythm. The study was conducted in emergency medical service (EMS) agencies and receiving hospitals in Seattle and King County, Washington. Prehospital cooling was initiated by EMS providers via rapid infusion of ≤2 L of 4°C normal saline after ROSC. All patients received standard care on hospital arrival with mild therapeutic hypothermia protocols involving surface and intravascular cooling devices for ≤24 hours with a goal temperature of <34°C.
Temperature at randomization was not significantly different between subgroups (≈36°C). The intervention group had decreased mean core temperature by 1 Bernard et al 18, 19 reported similar findings in a smaller randomized study in Australia. The authors randomized 234 resuscitated patients from VF arrest to paramedic-initiated cooling with a rapid infusion of 2 L of ice-cold lactated Ringer solution versus standard hospital-based therapeutic hypothermia (33°C) using surface cooling techniques. The intervention resulted in a modest decrease in core temperature of 0.8°C (34.4±1.2°C versus 35.2±1.0°C; P=0.001) on hospital arrival compared with the control group, although, core temperature equalized just 60 minutes after hospital arrival between groups (34.7±1.1°C versus 34.7±0.9°C; P=0.7). The primary end point defined as patients discharged directly home or to a rehabilitation facility was not significantly different between the paramedic-cooled group (47.5%) and hospital-cooled group (52.6%; P=0.043). The reported incidence of pulmonary edema and recurrent cardiac arrest during transport was not significantly different between groups.
Taking these trials together, the available data does not support the use of EMS-initiated rapid infusion of cold crystalloids as a mean to achieve faster cooling rates after ROSC in patients with or without VF arrest. These are disappointing findings because laboratory-based studies have previously suggested a relationship between early onset of therapeutic hypothermia and favorable outcomes in various animal models of cardiac arrest. 10, 12, 20 This lack of translation from benchto-bedside has several potential explanations.
First, in animal models, the best outcomes have been observed when cooling is achieved intra-arrest, 10 or immediately after ROSC. 12 In 1 animal study, a delay of only 15 minutes in the initiation of therapeutic hypothermia was enough to mitigate some of the neuroprotective benefits observed in the immediate cooling group. 12 This is an important methodological difference between animal and human studies, because therapeutic hypothermia after ROSC is currently achieved after several hours in humans (3 hours in patients without VF and 4.2 hours in VF-arrested patients in the Seattle trial intervention group).
Congruent with these human data is a study in 258 rats exposed to 10-minute asphyxial cardiac arrest then randomized to normothermia or cooling (33C°) at 30 minutes, 1, 4, and 8 hours after ROSC and maintained for either 24 or 48 hours. 20 IH initiated at 0 minute (45%), 1 hour (36%), and 4 hours (36%) after ROSC had similar survival, which was significantly better than that in the 8-hour group (14%) and normothermia group (17%). The Seattle and King County trial and animal data both suggest that there is no difference in survival so long as IH is initiated within 4 hours of arrest.
Second, in the Seattle and King County trial described above, the prehospital use of rapid cold saline infusion was associated with more episodes of rearrest en route, acidosis, and pulmonary edema on admission. Cardiac rearrest has the potential of causing further anoxic brain injury, acidosis is a known predictor of adverse outcomes and rapid cold saline infusion, at least in 1 cardiac arrest animal model, was associated with reduced coronary artery perfusion pressure compared with postresuscitation surface cooling methods. 21 These complications related to cold saline infusion did not affect early mortality in our study, but it is conceivable that they may have manifested because increased risk of death later during the hospitalization, thus, offsetting any potential benefit of achieving earlier hypothermia by rapid cold saline infusion.
Third, many factors contribute to outcomes after resuscitation. The quality and timing of bystander CPR, the performance and training of EMSs, and care by emergency and intensive care units are all critical elements and direct determinants of survival and functional outcomes. 22 The lack of survival benefit in our study must be interpreted in the context of the EMS and regional health system where the study was performed. We reported mortality rates of 35% for patients with VF, which are among the lowest in the United States. An important question remains whether the use of prehospital cooling might benefit patients in a less optimal EMS environment. For example, might prehospital cooling benefit patients who had a longer transit time before hospital arrival, or had longer EMS response times?
Potential Alternatives
Future outcome trials using faster, volume-sparing hypothermia methods during CPR or immediately after ROSC are clearly needed. As a preamble, Castrén et al 23 reported the safety, feasibility, and cooling efficacy of the RhinoChill device (BeneChill, Inc, San Diego, CA) during active CPR (intraarrest) in the Pre-ROSC IntraNasal Cooling Effectiveness study. RhinoChill is a transnasal evaporative cooling system that has been shown to improve the CPR success rate in a porcine model of cardiac arrest, explained by a higher increment in the coronary perfusion pressure compared with cooling with cold saline infusion. 24 Moreover, transnasal evaporative cooling seems to rapidly induce preferential brain cooling as compared with the rest of the body, which is cooled at a slower rate, creating a significant brain-body temperature gradient. 25 This small trial suggested that intra-arrest cooling with the RhinoChill device was feasible, relatively safe, and reduced the core temperatures by nearly 2 hours compared with hospital-based cooling systems. Larger randomized trials are ongoing to assess the effect of intra-arrest IH on clinically important outcomes. If these trials do not show benefit, the strategy of early, out-of-hospital cooling should be abandoned.
Hospital-Based Cooling
Initial clinical trials focused on hospital-based target core temperature of 32°C to 34°C, commonly referred to as mild therapeutic hypothermia, for an average of 12 to 24 hours. 13, 14 However, the hypothermia after cardiac arrest trial was criticized because the average temperature in the nonhypothermia control group remained >37°C, and some patients even developed fever between 8 and 36 hours after ROSC.
14 This has raised several questions of whether the improved survival and neurological outcomes seen at least in the hypothermia after cardiac arrest study were partly because of the therapeutic effects of induced mild hypothermia or the avoidance of fever/hyperthermia after the first 24 hours post OHCA. This becomes relevant because the development of hyperthermia during the first 36 to 48 hours postarrest seems to be associated with unfavorable outcomes in comatose patients with OHCA. 26, 27 Therefore, investigators conducted the temperature management to a target of either 33°C or 36°C after OHCA targeted temperature management (TTM) trial. 28 The investigators randomized a total of 939 patients with OHCA (≈80% with VF) to hospital-initiated cooling to a target temperature of 33°C (n=473) or 36°C (n=466), which was achieved by ice-cold fluids, ice packs, and intravascular or surface devices and maintained for 28 hours, after which, gradual rewarming was began, however, in unconscious patients temperature was maintained <37.5°C in both groups for 72 hours post OHCA using fever control measures.
Remarkably, the primary outcome of all-cause mortality (50% versus 48%; P=0.51) and secondary outcome of a composite of poor neurological function or death (54% versus 52%; P=0.78) through the end of the trial (180 days) were no different between the 33°C and 36°C group. The hazard ratio for death in multiple a priori subgroups, including age, time to ROSC, initial rhythm, and presence of shock at hospital admission, none of the point estimates showed a trend in the direction of a clinical benefit using 33°C as the target core temperature in the first 36 hours post OHCA resuscitation.
On the basis of these findings, the authors concluded that there was no evidence at this time to indicate that aiming for a body temperature of 33°C conferred any significant clinical benefits over a temperature of 36°C in unconscious patients admitted to the hospital after OHCA. One of the main hypotheses for this comparable clinical benefit seen with either hypothermia strategy has to do with the importance of avoiding the development of hyperthermia or fever during the active cooling intervention during the first 36 hours post cardiac arrest, and the subsequent days after the passive rewarming process.
Again, there are several plausible explanations for the lack of difference in survival or neurological outcome in the TTM trial. First, the majority of patients enrolled in the TTM had witnessed arrests, with bystander CPR initiated within a median of 1 minute after the onset of arrest. As such, they may have had less ischemia and reperfusion injury, and, therefore, a better overall prognosis than the average patient treated for OHCA. This is corroborated by the observation that >75% of patients in either the control or intervention group had a pupillary light reflex response at the time of admission. 28 Others have reported that ≈20% of patients resuscitated from OHCA have pupillary responses. 29 The presence of a pupillary response is one of the strongest predictors of good neurological outcome in the presence 30 or absence 29, 31 of IH/TTM. It seems plausible that the lack of difference in survival between the 33°C group and the 36°C group in the TTM trial may, in part, have been because patients in either group had a good overall prognosis and insufficient neurological or cardiac injury to benefit from IH/TTM. Second, the 33°C group had significantly more days receiving mechanical ventilation (median, 0.83 [0.67, 1.0] versus 0.76 [0.6, 10]; P=0.006) and were significantly less likely to have awoken before prognosis assessment (44% versus 52%; P=0.03) compared with the 36°C group. A strength of the TTM trial was that participating clinicians used a deferred, structured approach to prognosis assessment and withdrawal of care in enrolled subjects. 28 Unfortunately, this approach did not account for the prolonged metabolism of drugs in patients with deeper hypothermia. 32, 33 It seems plausible that the increased duration of ventilation and increased likelihood of unconsciousness at the time of prognosis assessment in the 33ºC group compared with the 36ºC group in the TTM trial was because of prolonged metabolism of sedatives.
Third, the estimated time from ROSC to achievement of a target temperature <33°C was ≈720 minutes. in the TTM trial. This was long compared with previous trials (Table) . This delay in reaching target temperature (may have) negated any clinical benefit.
Finally, propofol was commonly used as a sedative in the TTM trial (TTM Investigators, unpublished data, 2014). Cardioprotection from reperfusion injury was attenuated by propofol in a trial that of cardioprotection in patients undergoing coronary artery bypass grafting. 34 As well, in a systematic review of randomized trials of patients (n=696) undergoing bypass grafting, propofol was associated with significantly less myocardial ischemia and injury compared with sevoflurane. 35 It seems plausible that concurrent use of propofol may have attenuated the benefit of IH in the TTM trial.
Adoption of a target temperature range of 36°C may be associated with increased shivering as 36°C is close to the normal shivering threshold. [36] [37] [38] Shivering markedly increases heat production. 39 If endovascular methods of IH are used, skin counterwarming can be used to reduce the heat production and the shivering threshold. 40, 41 Limited trials have not demonstrated that one pharmacological method of reducing shivering is better than another in patients with cardiac arrest or normal volunteers. 38, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Medications commonly used to reduce shivering during IH include midazolam, fentanyl, dexmedetomidine, magnesium sulfate, meperidine, and buspirone.
Neuromuscular blocking agents (NMB) are sometimes used to reduce shivering. A systematic review of randomized trials in adults with acute respiratory distress syndrome (n=431) suggested that NMB reduce mortality as compared with no NMB. 53 A single-center randomized trial of NMB (rocuronium) in patients resuscitated from cardiac arrest has completed enrollment but not reported results (clinicaltrials.gov identifier NCT01683006). Until there is compelling evidence for or against use of NMB in patients with cardiac arrest, selection of NMB type and dose is at provider discretion.
Randomized trials completed to date have evaluated IH without other concurrent interventions. IH may have incremental benefit when combined with emergency cardiopulmonary support to improve cardiac output, 54 or hemofiltration to remove cytokines, 55 or xenon to increase neuroprotection. 56 These combination therapies remain investigational.
Conclusions
IH provides neuroprotection in animal models of cardiac arrest, but is of uncertain benefit in humans. Use of EMSinitiated rapid infusion of cold crystalloid as a means to achieve faster cooling rates after ROSC in patients with and without VF arrest did not improve survival. Whether intra arrest or volume-sparing cooling methods in the field are beneficial remain unclear. Initial trials of IH in patients hospitalized comatose after resuscitation from OHCA demonstrated benefit as compared with the control group. The lack of significant difference in survival or neurological outcome with temperature ranges of 33°C versus 36°C has increased uncertainty about which range and concurrent treatments are best. median of 1 minute after the onset of arrest. As such, they may have had less ischemia and reperfusion injury, and, therefore, a better overall prognosis than the average patient treated for OHCA. This is corroborated by the observation that >75% of patients in either the control or intervention group had a pupillary light reflex response at the time of admission. 28 Others have reported that ≈20% of patients resuscitated from OHCA have pupillary responses. 29 The presence of a pupillary response is one of the strongest predictors of good neurological outcome in the presence 30 or absence 29, 31 of IH/TTM. It seems plausible that the lack of difference in survival between the 33°C group and the 36°C group in the TTM trial may, in part, have been because patients in either group had a good overall prognosis and insufficient neurological or cardiac injury to benefit from IH/TTM. Second, the 33°C group had significantly more days receiving mechanical ventilation (median, 0.83 [0.67, 1.0] versus 0.76 [0.6, 10]; P=0.006) and were significantly less likely to have awoken before prognosis assessment (44% versus 52%; P=0.03) compared with the 36°C group. A strength of the TTM trial was that participating clinicians used a deferred, structured approach to prognosis assessment and withdrawal of care in enrolled subjects. 28 Unfortunately, this approach did not account for the prolonged metabolism of drugs in patients with deeper hypothermia. 32, 33 It seems plausible that the increased duration of ventilation and increased likelihood of unconsciousness at the time of prognosis assessment in the 33ºC group compared with the 36ºC group in the TTM trial was because of prolonged metabolism of sedatives.
IH provides neuroprotection in animal models of cardiac arrest, but is of uncertain benefit in humans. Use of EMSinitiated rapid infusion of cold crystalloid as a means to achieve faster cooling rates after ROSC in patients with and without VF arrest did not improve survival. Whether intra arrest or volume-sparing cooling methods in the field are beneficial remain unclear. Initial trials of IH in patients hospitalized comatose after resuscitation from OHCA demonstrated benefit as compared with the control group. The lack of significant difference in survival or neurological outcome with temperature ranges of 33°C versus 36°C has increased uncertainty about which range and concurrent treatments are best. 
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